Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Spark Therapeutics (ONCE) PT Lowered to $64 at Stifel
February 20, 2018 6:00 PM ESTStifel lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $73.00) while maintaining a Buy rating.
... MoreSpark Therapeutics (ONCE) PT Lowered to $100 at Cantor Fitzgerald; Reit. 'Overweight' Rating
February 20, 2018 1:33 PM ESTCantor Fitzgerald lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $100.00 (from $105.00) while maintaining an Overweight rating following Q4 results.
Analyst Elemer Piros commented, "We anticipate 2018 could become a transformative year for Spark with advancement of its hemophilia B program into Phase 3... More
